220 related articles for article (PubMed ID: 35763187)
1. Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.
van Velzen MJM; Creemers A; van den Ende T; Schokker S; Krausz S; Reinten RJ; Dijk F; van Noesel CJM; Halfwerk H; Meijer SL; Mearadji B; Derks S; Bijlsma MF; van Laarhoven HWM
Gastric Cancer; 2022 Sep; 25(5):906-915. PubMed ID: 35763187
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
4. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.
Lee DW; Lim Y; Kim HP; Kim SY; Roh H; Kang JK; Lee KH; Kim MJ; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
Cancer Res Treat; 2023 Jul; 55(3):927-938. PubMed ID: 36915247
[TBL] [Abstract][Full Text] [Related]
6. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
9. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F
Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199
[TBL] [Abstract][Full Text] [Related]
10. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.
Xi W; Zhou C; Xu F; Sun D; Wang S; Chen Y; Ji J; Ma T; Wu J; Shangguan C; Zhu Z; Zhang J
J Transl Med; 2022 Aug; 20(1):365. PubMed ID: 35962408
[TBL] [Abstract][Full Text] [Related]
11. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.
Guan S; Deng G; Sun J; Han Q; Lv Y; Xue T; Ding L; Yang T; Qian N; Dai G
Front Oncol; 2022; 12():926260. PubMed ID: 36081557
[TBL] [Abstract][Full Text] [Related]
13. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
[TBL] [Abstract][Full Text] [Related]
15. Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.
Chi Y; Su M; Zhou D; Zheng F; Zhang B; Qiang L; Ren G; Song L; Bu B; Fang S; Yu B; Zhou J; Yu J; Li H
Elife; 2023 Nov; 12():. PubMed ID: 37929934
[TBL] [Abstract][Full Text] [Related]
16. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
17. Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer.
Zhou H; Liu H; Li J; Wang J; Fu X; Li Y; Mao S; Du J
Genes Genomics; 2023 Aug; 45(8):1037-1046. PubMed ID: 37306927
[TBL] [Abstract][Full Text] [Related]
18. The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.
Liu B; Hu Z; Ran J; Xie N; Tian C; Tang Y; Ouyang Q
Breast; 2022 Oct; 65():116-123. PubMed ID: 35926241
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]